These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9187703)

  • 21. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance to longterm vasoactive intracavernous therapy.
    Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G
    Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intracavernous pharmacotherapy for organic impotence in the elderly].
    Richter S; Shalev M; Nissenkorn I
    Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term results of corpus cavernosum auto-injection therapy in treatment of patients with chronic erectile dysfunction].
    Gall H; Sparwasser C; Bähren W; Scherb W; Holzki G; Irion R
    Urologe A; 1992 Jan; 31(1):31-6. PubMed ID: 1553802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracavernosal injection therapy for impotence: preliminary results.
    Gilling PJ; Wright WL; Gray JM
    N Z Med J; 1988 Jun; 101(848):423-4. PubMed ID: 3393333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments.
    Kucuk EV; Tahra A; Bindayi A; Onol FF
    Andrology; 2016 Sep; 4(5):952-6. PubMed ID: 27368423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
    Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
    Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracavernous pharmacotherapy in psychogenic impotence.
    Weiss JN; Ravalli R; Badlani GH
    Urology; 1991 May; 37(5):441-3. PubMed ID: 1708925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient satisfaction with pharmacologic erection program.
    Hollander JB; Gonzalez J; Norman T
    Urology; 1992 May; 39(5):439-41. PubMed ID: 1580034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.
    Larsen EH; Gasser TC; Bruskewitz RC
    J Urol; 1987 Feb; 137(2):292-3. PubMed ID: 3806824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
    Kim SC; Seo KK; Park BD; Lee SW
    Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients.
    Girdley FM; Bruskewitz RC; Feyzi J; Graversen PH; Gasser TC
    J Urol; 1988 Nov; 140(5):972-4. PubMed ID: 3172370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracavernous injections of vasoactive substances for the treatment of impotence.
    Zorgniotti AW
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1620. PubMed ID: 3835353
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long-term prospective study.
    Althof SE; Turner LA; Levine SB; Risen CB; Bodner D; Kursh ED; Resnick MI
    J Sex Marital Ther; 1991; 17(2):101-12. PubMed ID: 1920466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why do so many people drop out from auto-injection therapy for impotence?
    Althof SE; Turner LA; Levine SB; Risen C; Kursh E; Bodner D; Resnick M
    J Sex Marital Ther; 1989; 15(2):121-9. PubMed ID: 2769773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.